About us

Benefit global patients and bridge the world by medtech innovation.

Global MedTech platform focusing
on high clinical need chronic diseases

Founded in 2021,EverBridge Group is a global diversified medical technology company focusing on high clinical need chronic diseases. Our mission is "Bridging Medtech Innovations from Asia to the World".

Adhering to the core philosophy of "rapid and high quality scaling", EverBridge Group has successfully built an enabling platform that accurately captures global industry trends and market demand to serve customers globally.

By leveraging the strong R&D capability of our state-of-the-art Medical Technology Research Institute,and the technical and manufacturing capability of our"Six Technology Centers",we have successfully executed on our innovative product roadmap.With the support of our unique "The EBS (EverBridge Business System)",a lean management approach,we have also rapidly scaled our business.In the global medical device market,EverBridge Group has won wide recognition and praise from customers globally for its comprehensive product portfolio,excellent product quality,efficient production capacity,and strong marketing and sales network.

EverBridge Group is dedicated to building a bridge fo medical technology innovation by actively developing global connections and communication to accelerate the advancement of medical technology.By collaborating with many outstanding global partners on better innovation and development of medical technology,we have provided cutting-edge,high-quality and affordable medical technology for patients with high-incidence chronic diseases around the world.We look forward to continuing to help patients globally achieve excellent treatment experiences and improved outcomes.

Providing innovative, high-quality, and accessible medical technology solutions to hundreds of millions of chronic disease patients worldwide, is the founding mission of EverBridge Group. We are committed to serving as a bridge for medical technology innovation in Asia and across the globe, enabling patients worldwide to benefit from exceptional treatments.

CEO of EverBridge GroupJay Wang

Committed to building a global medical technology platform in the field of high-incidence chronic diseases.

EverBridge Group was established.

06月
Focus on peripheral vascular, dedicated to scientific research and innovation.

The peripheral vascular business unit of EverBridge Group welcomes new strength joins.

09月
Join hands and move forward together to create a new future for neuroscience.

The Neuroscience business unit of EverBridge Group welcomes new strength joins.

03月
Cross national boundaries and serve the whole world!

Overseas expansion officially sets sail.

10月
Continuously deepen the exploration in the field of peripheral vascular vessels, and jointly build a new height in peripheral vascular medical care.

The peripheral vascular business unit of EverBridge Group welcomes new strength joins.

12月
Empower through the platformization of R&D technology to accelerate the pace of scientific and technological innovation.

The pilot implementation of the Underlying Technology Center is carried out.

06月
Precise diagnosis and treatment, jointly draw a new blueprint for tumor diagnosis and treatment.

joins hands with EverBridge Group to open a new chapter in the Integrated oncology diagnosis and treatment

07月
Continuously expand the territory of tumor diagnosis and treatment and jointly explore new fields.

Integrated oncology diagnosis and treatment treatment of EverBridge Group welcomes new strength joins.

08月
The three major growth engines of the global business of EverBridge Group are officially launched.

The operation of the 6 technology centers is launched.

01月
Deeply cultivate the field of neuroscience vertically and work together to create new medical solutions.

he neuroscience business unit of EverBridge Group welcomes new strength join.

02月
Value-based operation, innovate the future.

The EBS^™ excellence system is comprehensively implemented.

03月
The smart medical innovation center of the "Advanced MedTech Research Institutes" is established.

03月
Forged Strategic Collaboration with PulmonX

Adhering to an Open Commercialization Strategy of “Bringing In and Going Global”

05月
Everair（logo）as new member of the integrated oncology diagnosis and treatment business unit is officially launched.

Focusing on commercialization of chronic oncology management.

05月
Established at strategie partnership with Kaneka Medix Corponation.

02月
The product portfolio of the neuroscience business unit has been further strengthened.

02月
EverBridge Group Completes Series A Financing.

Increase investment in R&D innovation and expand into new clinical medical fields.

03月